Compounds > N-(4-ethoxyphenyl)-3-hydroxy-2-naphthalenecarboxamide
Page last updated: 2024-12-07

N-(4-ethoxyphenyl)-3-hydroxy-2-naphthalenecarboxamide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID78443
CHEMBL ID1388703
CHEBI ID122078
SCHEMBL ID2743100

Synonyms (49)

Synonym
OPREA1_239420
nsc 50690
4'-ethoxy-3-hydroxy-2-naphthanilide
unii-ed3vqi55t0
einecs 225-200-7
ec 225-200-7
ed3vqi55t0 ,
nsc50690
cibanaphthol rph
2-naphthalenecarboxamide, n-(4-ethoxyphenyl)-3-hydroxy-
2-naphtho-p-phenetidide, 3-hydroxy-
4711-68-6
nsc-50690
c.i. azoic coupling component 46
azoic coupling component 46
c.i. 37559
mls000736677 ,
c.i. azoic coupling component 30
naphthol as-vl
AG-690/36740014
n-(4-ethoxyphenyl)-3-hydroxy-2-naphthamide
CBDIVE_012078
n-(4-ethoxyphenyl)-3-hydroxy-naphthalene-2-carboxamide
3-hydroxy-2-naphtho-p-phenetidide
smr000528245
OPREA1_874331
CHEBI:122078
AKOS000592774
n-(4-ethoxyphenyl)-3-hydroxynaphthalene-2-carboxamide
NCGC00246827-01
CHEMBL1388703
HMS2886N22
DTXSID5063570
SCHEMBL2743100
bdbm80521
n-(4-ethoxyphenyl)-3-hydroxy-2-naphthalenecarboxamide
n-(4-ethoxyphenyl)-3-oxidanyl-naphthalene-2-carboxamide
cid_78443
3-hydroxy-n-p-phenetyl-2-naphthamide
Q27210711
sr-01000513141
SR-01000513141-1
azoic coupling component 30
dycosthol as-vl
ci 37559
CS-0362287
2-hydroxy-3-naphthoyl-p-ethoxyaniline
1-hydroxy-3-naphthoyl-p-ethoxy aniline
A918683
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
naphthalenecarboxamideAny member of the class of naphthalenes in which the naphthalene ring is directly attached to the carbonyl carbon of a carboxamide group.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (33)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency28.18380.003245.467312,589.2998AID2517
Chain A, Beta-lactamaseEscherichia coli K-12Potency25.11890.044717.8581100.0000AID485294
Chain A, JmjC domain-containing histone demethylation protein 3AHomo sapiens (human)Potency79.43280.631035.7641100.0000AID504339
LuciferasePhotinus pyralis (common eastern firefly)Potency0.75690.007215.758889.3584AID588342
acid sphingomyelinaseHomo sapiens (human)Potency39.810714.125424.061339.8107AID504937
BRCA1Homo sapiens (human)Potency3.54810.89137.722525.1189AID624202
ATAD5 protein, partialHomo sapiens (human)Potency5.48290.004110.890331.5287AID504466; AID504467
GLS proteinHomo sapiens (human)Potency11.22020.35487.935539.8107AID624170
TDP1 proteinHomo sapiens (human)Potency14.33940.000811.382244.6684AID686978; AID686979
Microtubule-associated protein tauHomo sapiens (human)Potency0.79430.180013.557439.8107AID1460
PINK1Homo sapiens (human)Potency50.11872.818418.895944.6684AID624263
nonstructural protein 1Influenza A virus (A/WSN/1933(H1N1))Potency1.77830.28189.721235.4813AID2326
ParkinHomo sapiens (human)Potency50.11870.819914.830644.6684AID624263
bromodomain adjacent to zinc finger domain 2BHomo sapiens (human)Potency56.23410.707936.904389.1251AID504333
NPC intracellular cholesterol transporter 1 precursorHomo sapiens (human)Potency1.25890.01262.451825.0177AID485313
parathyroid hormone/parathyroid hormone-related peptide receptor precursorHomo sapiens (human)Potency50.11873.548119.542744.6684AID743266
importin subunit beta-1 isoform 1Homo sapiens (human)Potency4.45375.804836.130665.1308AID540253; AID540263
DNA polymerase betaHomo sapiens (human)Potency8.91250.022421.010289.1251AID485314
mitogen-activated protein kinase 1Homo sapiens (human)Potency0.89130.039816.784239.8107AID1454
ras-related protein Rab-9AHomo sapiens (human)Potency2.81840.00022.621531.4954AID485297
serine/threonine-protein kinase PLK1Homo sapiens (human)Potency26.67950.168316.404067.0158AID720504
snurportin-1Homo sapiens (human)Potency4.45375.804836.130665.1308AID540253; AID540263
peptidyl-prolyl cis-trans isomerase NIMA-interacting 1Homo sapiens (human)Potency15.84890.425612.059128.1838AID504891
GTP-binding nuclear protein Ran isoform 1Homo sapiens (human)Potency8.19955.804816.996225.9290AID540253
DNA polymerase eta isoform 1Homo sapiens (human)Potency28.18380.100028.9256213.3130AID588591
DNA polymerase iota isoform a (long)Homo sapiens (human)Potency39.81070.050127.073689.1251AID588590
urokinase-type plasminogen activator precursorMus musculus (house mouse)Potency3.98110.15855.287912.5893AID540303
plasminogen precursorMus musculus (house mouse)Potency3.98110.15855.287912.5893AID540303
urokinase plasminogen activator surface receptor precursorMus musculus (house mouse)Potency3.98110.15855.287912.5893AID540303
gemininHomo sapiens (human)Potency16.36010.004611.374133.4983AID624296
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
DNA dC->dU-editing enzyme APOBEC-3G isoform 1Homo sapiens (human)IC50 (µMol)47.50000.270026.3638100.0000AID504723
DNA dC->dU-editing enzyme APOBEC-3A isoform aHomo sapiens (human)IC50 (µMol)12.90001.480014.526761.2000AID504724
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Major prion proteinOvis aries (sheep)EC50 (µMol)0.21200.21200.21200.2120AID759992
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (17)

Assay IDTitleYearJournalArticle
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1057861Inhibition of RML prion protein infected in mouse dividing ScN2a-cl3 cells expressing full length mouse PrP assessed as reduction of PrPsc level after 5 days by Western blotting analysis2013Bioorganic & medicinal chemistry, Dec-15, Volume: 21, Issue:24
Antiprion compounds that reduce PrP(Sc) levels in dividing and stationary-phase cells.
AID1057862Inhibition of RML prion protein infected in mouse dividing ScN2a-cl3 cells expressing full length mouse PrP assessed as reduction of PrPsc level after 5 days by ELISA2013Bioorganic & medicinal chemistry, Dec-15, Volume: 21, Issue:24
Antiprion compounds that reduce PrP(Sc) levels in dividing and stationary-phase cells.
AID612673Inhibition of rabbit muscle glycogen phosphorylase 1a assessed as release of phosphate from glucose-1- phosphate after 20 mins2011Bioorganic & medicinal chemistry, Aug-15, Volume: 19, Issue:16
Ligand-based modelling followed by synthetic exploration unveil novel glycogen phosphorylase inhibitory leads.
AID612672Inhibition of rabbit muscle glycogen phosphorylase 1a assessed as release of phosphate from glucose-1- phosphate at 10 uM after 20 mins2011Bioorganic & medicinal chemistry, Aug-15, Volume: 19, Issue:16
Ligand-based modelling followed by synthetic exploration unveil novel glycogen phosphorylase inhibitory leads.
AID759992Antiprion activity against sheep prion infected in mouse ScN2a-cl3 cells assessed as reduction in PrPSc level after 5 days by ELISA2013ACS medicinal chemistry letters, Jul-11, Volume: 4, Issue:7
Optimization of Arylamides as Novel, Potent and Brain-penetrant Antiprion Lead Compounds.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (8)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (12.50)29.6817
2010's6 (75.00)24.3611
2020's1 (12.50)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.25

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.25 (24.57)
Research Supply Index2.20 (2.92)
Research Growth Index4.44 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.25)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other8 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
amiodarone
Amiodarone: An antianginal and class III antiarrhythmic drug. It increases the duration of ventricular and atrial muscle action by inhibiting POTASSIUM CHANNELS and VOLTAGE-GATED SODIUM CHANNELS. There is a resulting decrease in heart rate and in vascular resistance.. amiodarone : A member of the class of 1-benzofurans that is 1-benzofuran substituted by a butyl group at position 2 and a 4-[2-(diethylamino)ethoxy]-3,5-diiodobenzoyl group at position 3. It is a cardiovascular drug used for the treatment of cardiac dysrhythmias.		2.08101-benzofurans;
aromatic ketone;
organoiodine compound;
tertiary amino compound		cardiovascular drug
amlodipine
Amlodipine: A long-acting dihydropyridine calcium channel blocker. It is effective in the treatment of ANGINA PECTORIS and HYPERTENSION.. amlodipine : A fully substituted dialkyl 1,4-dihydropyridine-3,5-dicarboxylate derivative, which is used for the treatment of hypertension, chronic stable angina and confirmed or suspected vasospastic angina.		2.0810dihydropyridine;
ethyl ester;
methyl ester;
monochlorobenzenes;
primary amino compound		antihypertensive agent;
calcium channel blocker;
vasodilator agent
carvedilol
[no description available]		2.0810carbazoles;
secondary alcohol;
secondary amino compound		alpha-adrenergic antagonist;
antihypertensive agent;
beta-adrenergic antagonist;
cardiovascular drug;
vasodilator agent
fendiline
Fendiline: Coronary vasodilator; inhibits calcium function in muscle cells in excitation-contraction coupling; proposed as antiarrhythmic and antianginal agents.		2.0810diarylmethane
apomorphine
Apomorphine: A derivative of morphine that is a dopamine D2 agonist. It is a powerful emetic and has been used for that effect in acute poisoning. It has also been used in the diagnosis and treatment of parkinsonism, but its adverse effects limit its use.		2.0810aporphine alkaloidalpha-adrenergic drug;
antidyskinesia agent;
antiparkinson drug;
dopamine agonist;
emetic;
serotonergic drug
acepromazine
Acepromazine: A phenothiazine that is used in the treatment of PSYCHOSES.. acepromazine : A member of the class of phenothiazines that is 10H-phenothiazine substituted by an acetyl group at position 2 and a 3-(dimethylamino)propyl group at position 10.		2.0810aromatic ketone;
methyl ketone;
phenothiazines;
tertiary amino compound		phenothiazine antipsychotic drug
dihydroergotamine
Dihydroergotamine: A 9,10alpha-dihydro derivative of ERGOTAMINE. It is used as a vasoconstrictor, specifically for the therapy of MIGRAINE DISORDERS.. dihydroergotamine : Ergotamine in which a single bond replaces the double bond between positions 9 and 10. A semisynthetic ergot alkaloid with weaker oxytocic and vasoconstrictor properties than ergotamine, it is used (as the methanesulfonic or tartaric acid salts) for the treatment of migraine and orthostatic hypotension.		2.0810ergot alkaloid;
semisynthetic derivative		dopamine agonist;
non-narcotic analgesic;
serotonergic agonist;
sympatholytic agent;
vasoconstrictor agent
congo red
Congo Red: An acid dye used in testing for hydrochloric acid in gastric contents. It is also used histologically to test for AMYLOIDOSIS.. Congo Red : An indicator dye that is blue-violet at pH 3.0 and red at pH 5.0.		2.0810bis(azo) compound
ethoxazene
[no description available]		2.0810azobenzenes
tetrandrine
tetrandrine: a bisbenzylisoquinoline that exhibits antifibrogenic activity		2.0810bisbenzylisoquinoline alkaloid;
isoquinolines
desloratadine
desloratadine: major metabolite of loratadine. desloratadine : Loratadine in which the ethoxycarbonyl group attached to the piperidine ring is replaced by hydrogen. The major metabolite of loratidine, desloratadine is an antihistamine which is used for the symptomatic relief of allergic conditions including rhinitis and chronic urticaria. It does not readily enter the central nervous system, so does not cause drowsiness.		2.0810benzocycloheptapyridineanti-allergic agent;
cholinergic antagonist;
drug metabolite;
H1-receptor antagonist
quinoprazine
quinoprazine: structure given in first source		2.0810
2-[[[4-(methylthio)anilino]-oxomethyl]amino]benzamide
[no description available]		2.0610ureas
resveratrol
trans-resveratrol : A resveratrol in which the double bond has E configuration.		2.0810resveratrolantioxidant;
phytoalexin;
plant metabolite;
quorum sensing inhibitor;
radical scavenger
tamoxifen
[no description available]		2.0810stilbenoid;
tertiary amino compound		angiogenesis inhibitor;
antineoplastic agent;
bone density conservation agent;
EC 1.2.3.1 (aldehyde oxidase) inhibitor;
EC 2.7.11.13 (protein kinase C) inhibitor;
estrogen antagonist;
estrogen receptor antagonist;
estrogen receptor modulator
Licarin A
[no description available]		2.0610benzofurans
ConditionIndicatedRelationship StrengthStudiesTrials
Innate Inflammatory Response
[description not available]		02.0510
Inflammation
A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.		02.0510